Investors in Recursion (NASDAQ: RXRX) seemed only mildly fazed by Wednesday’s series of company announcements. The artificial intelligence (AI)-based drug developer’s stock barely moved on Wednesday, ...
For decades, scientists have known that motor proteins like kinesin-2 ferry vital cargo along microtubule "highways" inside cells. But how these molecular vehicles identify and bind to the right cargo ...
Creating simple data classes in Java traditionally required substantial boilerplate code. Consider how we would represent Java’s mascots, Duke and Juggy: public class JavaMascot { private final String ...
A mysterious object from interstellar space is screaming through our solar system right now, and is expected to rip past Mars and Jupiter over the coming months before exiting back into the void ...
For multivariate distributions in the domain of attraction of a max-stable distribution, the tail copula and the stable tail dependence function are equivalent ways to capture the dependence in the ...
Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top of ...
As U.S. stocks recover from recent tariff tumult, investors should be on alert for rising "tail risks," according to Stephen Dover, chief market strategist and head of the Franklin Templeton Institute ...
(RTTNews) - Recursion Pharmaceuticals, Inc. (RXRX), a clinical-stage TechBio company, on Monday, announced that it is deprioritizing three of its clinical programs and one preclinical program ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback